Treatment of macular edema due to retinal vein occlusions

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 705-713

  Channa, Roomasa ^a   Smith, Michael ^a   Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dexamethosone implant; Ischemia; Sustained release; Triamcinolone acetonide; Vascular endothelial growth factor; Vascular leakage

Indexed keywords

DEXAMETHASONE; RANIBIZUMAB; STEROID; TRIAMCINOLONE ACETONIDE;

BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; HUMAN; INCIDENCE; LASER COAGULATION; PATHOGENESIS; PATIENT CARE; PREVALENCE; RETINA MACULA EDEMA; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR;

EID: 79958787885     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S7632     Document Type: Review

References (20)

1. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313-319.
2. Klein R, Klein BEK, Lee KE, Cruickshanks KJ, Gangnon RE. Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am J Ophthalmol. 2006;142:531-539.
3. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126:513-518.
4. Turello M, Pasca S, Daminato R, et al. Retinal vein occlusion: evaluation of "classic" and "emerging" risk factors and treatment. J Thromb Thrombolysis. 2010;29:459-464.
5. Green WR, Chan CC, Hutchins GM, Terry JM. Central vein occlusion: a prospective histological study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc. 1981;79:371-421.
6. The Branch Vein Occlusion Study Group. Argon laser photocoagula-tion for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271-282.
7. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The central vein occlusion study group M report. Ophthalmology. 1995;102: 1425-1433.
8. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859-870.
9. Campochiaro PA, Hafz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator. Molec Ther. 2008;16:791-799.
10. Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology. 2008;115:47-54.
11. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravit-real ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009;147:298-306.
12. Brown DM, Campochiaro PA, Singh R P, et al. Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion: 6-month results of the phase III CRUISE study. Ophthalmology. 2010;117:1124-1133.
13. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study. Ophthalmology. 2010;117: 1102-1112.
14. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011; In press.
15. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011. In press.
16. Campochiaro PA, Hafz G, Channa R, et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusion: two-year outcomes. Ophthalmology. 2010;117:2387-2394.
17. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion. The standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127: 1101-1114.
18. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch vein occlusion. The standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115-1128.
19. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamthasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128: 289-296.
20. Campochiaro PA, Choy DF, Do DV, et al. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology. 2009;116: 2158-2164.